BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasonov EL. Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. Pulʹmonologiâ (Mosk ) 2020;30:629-44. [DOI: 10.18093/0869-0189-2020-30-5-629-644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Sharipova MМ, Ivkina MV, Arkhangelskaya AN, Gurevich KG. Peculiarities of the course of COVID-19 in patients with chronic noncommunicable diseases (literature review). Russian Journal of Physiotherapy, Balneology and Rehabilitation 2022;20:525-534. [DOI: 10.17816/rjpbr106858] [Reference Citation Analysis]
2 Andreev SS, Isaev TK, Trushkin RN, Kantimerov DF. Complicated urinary tract infection in a patient with severe COVID-19. jour 2021;20:68-74. [DOI: 10.52420/2071-5943-2021-20-5-68-74] [Reference Citation Analysis]
3 Kruglova TS, Fomina DS, Poteshkina NG, Frolova NF, Beloglazova IP, Mutovina ZY, Samsonova IV, Kovalevskaja EA, Zagrebneva AI, Serdotetckova SA, Chernov AA, Lysenko MA. Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19. Terapevticheskii arkhiv 2021;93:1316-24. [DOI: 10.26442/00403660.2021.11.201248] [Reference Citation Analysis]
4 Malyarchikov AV, Shаpovаlov KG, Lukyanov SA, Tereshkov PP, Kazantseva LS. Activity of Negative Regulation of the PD-1/PD-L1/PD-L2 T-Cell Response System in Patients with Pneumonia and Influenza A (H1N1). Obŝaâ reanimatologiâ 2021;17:4-11. [DOI: 10.15360/1813-9779-2021-4-4-11] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Malyarchikov AV, Shаpovаlov KG, Lukyanov SA, Kazantseva LS. Role of proteins MRP8 (S100A8) and MRP14 (S100A9) in the development of critical condition in patients with pneumonia with A/H1N1 influenza. Acta biomedica scientifica 2021;6:70-76. [DOI: 10.29413/abs.2021-6.3.7] [Reference Citation Analysis]